Call Today:

Tel: +1 (844) 792-6300


  • Facebook - White Circle
  • Twitter - White Circle
  • Instagram - White Circle
  • LinkedIn - White Circle

Order Now:

Fax: 267.224.4436

Thrombolex, Inc.
75 Britain Drive

New Britain, PA 18901​

© 2020 by Thrombolex™   |   All Rights Reserved    |    Disclaimers    

Home / Dr. Anthony Comerota

Scientific Advisory Board
Anthony Comerota,

Medical Director Inova General Hospital, Arlington, VA. Dr. Comerota was previously a faculty member at the Temple University Health Sciences Center and Chief of Vascular Surgery, Program Director in General and Vascular Surgery, President of the Medical Staff, and President of the Medical Alumni Association.


Dr. Comerota served as Director of the Jobst Vascular Institute at ProMedica Toledo Hospital from 2002-2015 and Executive Director of Research at ProMedica and Jobst Vascular Institute from 2015-2016. He also serves as editorial board member of Vascular and Endovascular Surgery and Annals of Vascular Surgery.


Dr. Comerota has been a major contributor to the development of some of the newest forms of treatment for vascular disease and has been the principal investigator of seven major national trials and a coinvestigator on several others. He is a member of several professional societies and has written 7 textbooks and authored more than 300 publications.

Quality of Life

“Everybody will receive anti-coagulation medicine, but patients who have their clot removed, have a much better quality of life”


                   -  Dr. Anthony Comorota

                            Thrombolex SAB

Available Now:

The BASHIR™ Endovascular Catheter is a device intended for the localized infusion of physician specified fluids, including thrombolytics, into the peripheral vasculature.

The BASHIR™ N-X Endovascular Catheter is a device intended for the localized infusion of physician specified fluids, into the peripheral vasculature, including the pulmonary arteries.

Need more details? Contact us.

We are here to assist. Contact us by phone, email or via our social media channels.